Title: Assessing quality of life and depression in psoriasis patients: A cross-sectional study

Short running title: QoL and depression in psoriasis

**Yonatan Kok^{1,2}, Anna Braue^{1,2}, Raymond Martyres^{1,2,3}
and George Varigos^{1,2}**

¹The University of Melbourne, Department of Medicine, Parkville, Victoria, Australia

²The Royal Melbourne Hospital, Department of Dermatology, Parkville, Victoria, Australia

³The Royal Melbourne Hospital, Department of General Medicine, Parkville, Victoria, Australia

Corresponding author: Yonatan Kok

Postal address: 37 Doherty Street, Deer Park, Victoria, Australia, 3023

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/AJD.13116](https://doi.org/10.1111/AJD.13116)

This article is protected by copyright. All rights reserved

Email address: yonathan.kok@gmail.com

Telephone number: +61 434644543 (primary number) or (03) 83619391 or (03) 93427000

Acknowledgments

We would like to acknowledge the Australasian Psoriasis Registry for their contribution and support in this study.

Conflict of interest

The authors of this study do not have any conflict of interest that would influence the author's objectivity.

2019

DR. YONATAN KOK (Orcid ID : 0000-0002-0604-1183)

Article type : Research Letter

Author Manuscript

Assessing quality of life and depression in psoriasis patients: A cross-sectional study

Manuscript

Psoriasis is a chronic, auto-immune skin condition with a severe impact on mental health and marked quality of life impairment due to its effect on cosmesis and physical function^{1,2}. Depression is common in psoriasis patients with an estimated prevalence rate of 30%¹. It has been shown to account for the significant portion of quality impairment in the Dermatology Life Quality Index (DLQI) that could not otherwise be explained by the low Psoriasis Area Severity Index (PASI)^{3,4}. A literature review has recently shown that the DLQI has major weaknesses in reporting the mental and emotional aspects of quality of life⁵. The Beck Depression Inventory-II (BDI-II) is a clinical instrument commonly used in psychiatry to screen for depression, but its use is not currently a standard practice in dermatology⁶. This letter analyses the DLQI's ability to detect depression in psoriasis patients and evaluates the association between the domains of quality of life in the DLQI and depression.

This prospective cross-sectional study was conducted at The Royal Melbourne Hospital dermatology outpatient's clinic, a tertiary referral centre, in Australia. Forty-five

adult patients with psoriasis of all types were recruited and their PASI, DLQI and BDI-II scores were collected. Total DLQI scores were categorised into low (0 to 10) or high (11 to 30) as per the Australian psoriasis treatment consensus⁷.

Across the low and high DLQI groups, patient demographic data were similar, but, the high DLQI group had a higher proportion of females and visible lesions on their skin (table 1). The overall prevalence rate for depression in this study was 13.3%.

The correlations between total PASI, DLQI and BDI-II scores were all found to be statistically significant. The correlation between the DLQI and BDI-II was the strongest with a Spearman's rho value of 0.52 ($p < 0.01$). The Spearman's rho correlation between the PASI and DLQI and, PASI with BDI-II, were weak with values of 0.47 ($p < 0.01$) and 0.36 ($p < 0.01$) respectively. Using Fisher's r to z transformation, differences in all of the correlation values were not statistically significant.

To explore the clinical value of using the PASI and DLQI for predicting depression in psoriasis patients, this study calculated the sensitivity, specificity, positive predictive value and negative predictive value for 4 possible PASI and DLQI score combinations (table 2). It was found that a high DLQI score alone produced a sensitivity of only 50% for depression. Either one of the DLQI or PASI score being high produced the highest negative predictive value of 91%. Both a high PASI and DLQI score had the highest specificity and positive predictive value of 92% and 40% respectively.

As a whole, all the domains in the DLQI shared a significant association with total BDI-II scores with symptoms and feelings, leisure and treatment burden being the strongest (table 3). Differences were noted when the correlation was measured in the context of patient socio-demographic variables. Patients with a mild PASI score showed a significant association in all the domains of the DLQI excluding occupation. Patients with moderate to severe PASI score were found to only have significant associations in leisure and treatment burden. Comparing for age, young patients showed highly significant findings on all the domains of the DLQI, whereas the older patient group had significant findings only for symptoms and feelings and treatment burden. Differences in gender revealed that impairment in daily activities was significantly associated with a higher BDI-II score for females, whilst disturbance in relationship was more statistically important for male psoriasis patients. Patients identified as having no co-morbidities showed significant associations in all domains of the DLQI apart from occupation, whereas patients having additional co-morbidities had significant findings only in symptoms and feelings and treatment burden. Finally, all the domains of the DLQI were significantly associated with the BDI-II in patients with visible plaque lesions. When these lesions were coverable, symptoms and feelings was the only domain significantly associated with the BDI-II. Joint involvement,

This article is protected by copyright. All rights reserved

smoking, alcohol, psoriasis type and treatment type were not assessed as they had significant asymmetrical distributions.

The evidence presented here suggests that whilst quality of life, disease severity and depression are linked, both the PASI and DLQI have a low sensitivity for detecting clinical depression in psoriasis patients. The use of more psychologically oriented tools, such as the BDI-II, could therefore aid clinicians in detecting and managing depression early. Focus should be given to patients who report impairment in the domains of symptoms and feelings, leisure and treatment burden due to its increased association with depression.

References

1. Baker CS, Foley PA, Braue A. Psoriasis uncovered - measuring burden of disease impact in a survey of Australians with psoriasis. *Australasian Journal of Dermatology* 2013;54:1-6.

2. de Korte J, Sprangers MAG, Mommers FMC et al. Quality of Life in Patients with Psoriasis: A Systematic Literature Review. *Journal of Investigative Dermatology Symposium Proceedings* 2004;9(2):140-7.
3. Schmitt J, Ford DE. Psychiatric–Medical Comorbidity: Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis — a structural equations modeling approach. *General Hospital Psychiatry* 2007;29:134-40.
4. Schmitt JM, Ford DE. Role of Depression in Quality of Life for Patients with Psoriasis. *Dermatology* 2014.
5. Both H, Essink-Bot M-L, Busschbach J et al. Critical Review of Generic and Dermatology-Specific Health-Related Quality of Life Instruments. *Journal of Investigative Dermatology* 2007;127(12):2726-39.
6. Beck AT, Steer RA, Brown GK. BDI-II, Beck depression inventory : manual. San Antonio, Tex.; Boston: Psychological Corp. ; Harcourt Brace; 1996.
7. Baker C, Mack A, Cooper A et al. Treatment goals for moderate to severe psoriasis: An Australian consensus. *Australasian Journal of Dermatology* 2013(2):148.

Table 1

The basic demographic data of adult psoriasis patients in this study by level of DLQI impairment.

	Low DLQI (n = 35)	High DLQI (n = 10)	Total
Age			
Mean years (SD)	51 (13.9)	45 (14.7)	
Young (%)	23 (66%)	6 (60%)	29 (64%)
Old (%)	12 (34%)	4 (40%)	16 (36%)
Gender (%)			
Male	18 (51%)	3 (30%)	21 (47%)
Female	17 (49%)	7 (70%)	24 (53%)
Psoriasis type (%)			
Chronic plaque	30 (86%)	10 (100%)	40 (89%)
Palmoplantar	4 (11%)	0 (0%)	4 (9%)
Guttate	1 (3%)	0 (0%)	1 (2%)
Lesion visibility (%)			

Visible	21 (60%)	9 (90%)	30 (67%)
Hidden	14 (40%)	1 (10%)	15 (33%)
Co-morbidities (%)			
Present	13 (37%)	3 (30%)	16 (36%)
Absent	22 (63%)	7 (70%)	29 (64%)
Joint involvement (%)			
Present	7 (20%)	1 (10%)	8 (18%)
Absent	28 (80%)	9 (90%)	37 (82%)
Smoking (%)			
Yes	4 (11%)	1 (10%)	5 (11%)
No	31 (89%)	9 (90%)	40 (89%)
Alcohol (%)			
Yes	7 (20%)	3 (30%)	10 (22%)
No	28 (80%)	7 (70%)	35 (78%)
Treatment type (%)			
Topical	3 (8%)	0 (0%)	3 (7%)
Phototherapy	1 (3%)	0 (0%)	1 (2%)
Oral systemic	5 (14%)	5 (50%)	10 (22%)
Biologic	24 (69%)	4 (40%)	28 (62%)
Combination	2 (6%)	1 (10%)	3 (7%)

Table 2

The sensitivity, specificity, positive predictive value and negative predictive value of a high PASI and/or DLQI score for depression in adult psoriasis patients

Sensitivity	Specificity	PPV [†]	NPV [‡]

High PASI	33%	90%	33%	90%
High DLQI	50%	82%	30%	91%
Either DLQI or PASI high	50%	79%	27%	91%
Both DLQI and PASI high	33%	92%	40%	90%

Note. A high score in the DLQI or PASI means it is within the moderate to severe range

[†]means positive predictive value

[‡]means negative predictive value

Table 3

Spearman's correlation values between the domains of the DLQI and BDI-II total score according to PASI severity and patient socio-demographic variables

DLQI domains	PASI			Age [‡]		Gender		Co-morbidities		Visibility	
	Total cohort	Mild	Mod to severe [†]	Old	Young	Male	Female	Present	Absent	Visible	Hidden
Symptoms and feelings	0.54**	0.43**	0.60	0.48**	0.60*	0.62**	0.48*	0.71**	0.43*	0.47**	0.63*
Daily activities	0.44**	0.32*	0.81	0.29	0.65*	0.42	0.46*	0.50	0.42*	0.44*	0.26
Leisure	0.51**	0.38*	0.94**	0.33	0.70**	0.52**	0.52**	0.50	0.55**	0.53**	0.26
Occupation	0.32*	0.28	0.54	0.28	0.43*	0.43	0.23	0.38	0.28	0.27*	0.32
Relationship	0.43**	0.33*	0.81	0.29	0.61*	0.52**	0.40	0.48	0.43*	0.44*	0.36
Treatment burden	0.53**	0.44**	0.84*	0.44*	0.64**	0.58**	0.45*	0.66**	0.48**	0.55**	0.26

Note. * means $p < 0.05$ and ** means $p < 0.01$

[†]This is the abbreviated version of the moderate to severe PASI group. A moderate to severe PASI is classified as a score of greater than 10.

[‡] The age groups are defined as young, being between the ages of 0 to 50 years-old, and, old as being above 50 years-old.

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Kok, Y;Braue, A;Martyres, R;Varigos, G

Title:

Assessing quality of life and depression in psoriasis patients: A cross-sectional study

Date:

2019-07-18

Citation:

Kok, Y., Braue, A., Martyres, R. & Varigos, G. (2019). Assessing quality of life and depression in psoriasis patients: A cross-sectional study. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 61 (1), pp.E133-E135. <https://doi.org/10.1111/ajd.13116>.

Persistent Link:

<http://hdl.handle.net/11343/286164>